(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 18 October 2001 (18.10.2001)

PCT

(10) International Publication Number WO 01/76661 A1

(51) International Patent Classification7: A61M 1/34, 1/16

[IT/IT]; Via S. Martino Carano, 84, I-41037 Mirandola (IT).

(21) International Application Number: PCT/IB01/00544

(74) Agent: LEJEUNE, Daniel; Hospal Service Brevets, 61,

(22) International Filing Date: 2 April 2001 (02.04.2001)

avenue Tony Garnier, F-69007 Lyon (FR).

(25) Filing Language:

(81) Designated States (national): AU, CA, US.

(26) Publication Language:

English

English

(30) Priority Data:

TO2000A000333

7 April 2000 (07.04.2000)

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicant (for all designated States except US): HOSPAL AG [CH/CH]; Dornacherstrasse 8, CH-4008 Basel (CH).

Published:


with international search report

(72) Inventor; and

(75) Inventor/Applicant (for US only): PEDRAZZI, Renato

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DEVICE AND METHOD FOR CONTROLLING INFUSION OF A LIQUID IN AN EXTRACORPOREAL BLOOD CIRCUIT



(57) Abstract: A Dialysis machine comprises: an extracorporeal blood circuit having an arterial pipe (12) and a venous pipe (15) respectively connected to an inlet and an outlet of a blood compartment (5) of a filter (4) having a blood compartment (5) and a dialysis liquid compartment (6) separated by a semi-permeable membrane (7); means (31) for determining a sequence of infusion of a liquid in the extracorporeal blood circuit, from at least one characteristic value (FF, TMP_{ave}, K_{ut}) correlated with the concentration of the blood (C_E and/or a filtration efficiency of the filter (4); and means for infusing the infusion solution in the arterial pipe (12) and in the venous pipe (15) in accordance with the determined infusion sequence.

DEVICE AND METHOD FOR CONTROLLING INFUSION OF A LIQUID IN AN EXTRACORPOREAL BLOOD CIRCUIT

The present invention relates to a device and method for infusing a liquid in an extracorporeal blood circuit of a dialysis machine.

As is well known, blood is composed of a liquid part called blood plasma and a corpuscular part formed by the blood cells, including, among others, the red blood cells. In cases of renal insufficiency, apart from the aforementioned components, the blood also contains metabolic waste (urea, creatinine) in excess which must be removed by means of a dialysis treatment effected by a dialysis machine.

A dialysis machine a generally comprises:

15

25

- a filter (dialyzer) comprising a blood compartment and a dialysis liquid compartment separated from one another by a semi-permeable membrane
- an extracorporeal blood circuit, which is connected to the blood compartment of the filter; and
- a dialysis liquid circuit, which is connected to the dialysis liquid compartment of the filter.

In use, the blood to be treated and a dialysis liquid
respectively pass through these compartments, generally
flowing in counter-current.

During dialysis treatment, there is migration of metabolic waste from the blood compartment to the dialysis liquid compartment through the semipermeable membrane by diffusion. Metabolic waste is also transferred by convection, from the blood compartment to the dialysis liquid compartment,

2

when ultrafiltration of plasma water is caused through the membrane in order that the patient lose a determined weight during the treatment.

To increase the efficiency of dialysis treatment, it is also known to cause the ultrafiltration of large amounts of plasma water, so as to enhance the effects of transport of the undesirable waste by convection. The quantity of plasma water removed in excess relative to the desired final weight loss is compensated with a substitution liquid, which is infused into the extracorporeal blood circuit. The substitution liquid is the infused either upstream from filter (pre-dilution downstream from technique) or the filter (post-dilution The infusion liquid generally consists of a technique). solution with physiological composition and concentration.

10

15

20

25

Both pre-dilution and post-dilution techniques have their respective advantages and disadvantages.

In the post-dilution technique, the plasma water removed through the membrane is more concentrated than in the predilution technique and, at equal flows, the treatment is more efficient. On the other hand, with the post-dilution technique, blood becomes more easily concentrated, which can slower the blood flow in the filter as well the ultrafiltration of plasma water (through partial clogging of the filter itself), giving rise to the phenomenon called filter "caking". Consequently, the post-dilution technique permits extraction of a more limited quantity of plasma water than with the pre-dilution technique.

With the pre-dilution technique, the critical conditions leading to "caking" are avoided and the ultrafiltration

3

efficiency is increased. However, at equal flows, the predilution technique is less efficient than the post-dilution technique.

The aim of the present invention is to provide a device and a method for infusing a liquid into an extracorporeal blood circuit of a dialysis machine that do not have the drawbacks described above.

According to the present invention, a dialysis machine comprises:

- a filter having a blood compartment and a dialysis liquid compartment separated by a semi-permeable membrane;
 - an extracorporeal blood circuit having an arterial pipe connected to an inlet of the blood compartment and a venous pipe connected to an outlet of the blood compartment;
- a dialysis liquid circuit having a supply pipe connected to an inlet of the dialysis liquid compartment and a drain pipe connected to an outlet of the dialysis liquid compartment;
- a infusion circuit having a pre-dilution pipe connected
 to the arterial pipe and a post-dilution pipe connected to the venous pipe;
 - means for varying the flow of an infusion liquid in the pre-dilution pipe and in the post-dilution pipe, and
- control means for controlling the flow varying means so
 that the flow of the infusion liquid in the pre-dilution pipe and the post-dilution pipe matches a determined sequence.

The dialysis machine according to the invention may comprise one or more or the following features:

4

- the control means comprises means for determining the infusion sequence from at least one characteristic value (FF, TMPave, Kuf) correlated with the concentration of the blood (CE) and/or the filtration efficiency of the filter.
- the control means comprises means for comparing the characteristic value (FF, TMPave, Kuf) with a series of intervals (I1...x, IT1...x, IK1...x), each interval (I1...x, IT1...x, IT1...x, IK1...x)
- the infusion varying means comprises a valve means for alternately occluding the pre-dilution pipe and the post-dilution pipe, and the predetermined control signal (G) defines a sequence for opening and closing the valve means.
- the infusion varying means comprises an infusion pump for circulating the infusion liquid, and the predetermined control signal (L) is for regulating the flow rate (IR) of liquid generated by the infusion pump.
 - the dialysis machine comprises a ultrafiltration pump for causing ultrafiltration of plasma water through the membrane of the filter, and the predetermined control signal (S) is for regulating the flow rate (UFR) of liquid generated by the ultrafiltration pump.

20

25

- the dialysis machine comprises a bubble trap connected to the arterial pipe and a bubble trap connected to the venous pipe and means for injecting or withdrawing air into/from the bubble traps so as to adjust the level of liquid therein, and in the predetermined control signal (S) is for controlling the

5

means for injecting or withdrawing air into/from the bubble traps.

- the dialysis machine comprises:
- means for determining a ultrafiltration flow rate (UFR)
 of plasma water through the membrane of the filter;
 - means for determining the haematocrit (Hct) at the inlet of the filter, and
 - means for calculating the characteristic value as a filtration factor (FF) equal to UFR/[Qb(1-Hct)].
- 10 the dialysis machine comprises:

15

20

- \bullet means for measuring the blood pressure values (Pbo, Pbi) at the inlet and at the outlet of the blood compartment of the filter;
- means for measuring the dialysis liquid pressure values
 (Pdi, Pdo) at the inlet and at the outlet of the dialysis
 liquid compartment of the filter;
 - means for calculating an inlet transmembrane pressure value (TMPi) as the difference between the pressure value (Pbi) at the inlet of the blood compartment and the pressure value (Pdo) at the outlet of the dialysis liquid compartment and an outlet transmembrane pressure value (TMPo) as the difference between the pressure value (Pbo) at the outlet of the blood compartment and the pressure value (Pdi) at the inlet of the dialysis liquid compartment;
- means for calculating the characteristic value as a mean transmembrane pressure value (TMPave) equal to [TMPi- TMP_0]/2.
 - the dialysis machine comprises:

10

25

- means for determining a ultrafiltration flow rate (UFR)
 of plasma water through the membrane of the filter;
- means for calculating the characteristic value as an actual permeability ($K_{\rm Uf}$) equal to the ratio between the ultrafiltration flow rate (UFR) and the mean transmembrane pressure value ($TMP_{\rm ave}$).

Another object of the present invention is a method for infusing an infusion liquid into an extracorporeal blood circuit of a dialysis liquid machine, the extracorporeal blood circuit having an arterial pipe connected to an inlet of a blood compartment of a filter, and a venous pipe connected to an outlet of the blood compartment, the filter having a blood compartment and a dialysis liquid compartment separated by a semi-permeable membrane,

characterized in that it comprises the steps of;

- determining an infusion sequence from at least one characteristic value (FF, $TMP_{\rm ave}$, $K_{\rm uf}$) correlated with the concentration of the blood (CE) and/or a filtration efficiency of the filter, and
- infusing the infusion solution in either one or both of the arterial pipe and in the venous pipe in accordance with the determined infusion sequence.

For better understanding of the present invention an embodiment thereof will now be described, referring to the appended drawings, in which:

- Figure 1 is a schematic representation of a dialysis machine;

7

- Figure 2 is a schematic representation of a detail of the machine of figure 1; and

- Figure 3 is a schematic representation of a variant of the detail in figure 2.

In figure 1, a dialysis machine 1 comprises an extracorporeal blood circuit 2, a dialysis liquid circuit 3 and a filter 4 (dialyzer) having a blood compartment 5 and a dialysis liquid compartment 6 separated by a semi-permeable membrane 7.

The extracorporeal blood circuit 2 comprises an arterial pipe 12 and a venous pipe 15, respectively connected to an inlet and an outlet of the blood compartment 5 of the filter 4. The arterial pipe 12 is fitted with a peristaltic pump 13 supplying a blood flow Q_D and a bubble trap 14, and the venous pipe 15 is fitted with a bubble trap 16.

The dialysis liquid circuit 3 comprises a supply pipe 17 and a drain pipe 18, respectively connected to an inlet and an outlet of the dialysis liquid compartment 6 of the filter 4. The supply pipe 17 is fitted with a pump 19 supplying a fresh dialysis liquid flow Qdi and the drain pipe 18 is fitted with a pump 20 supplying a used liquid flow Qdo. In Use, the upstream end of the supply pipe 17 is connected to a source of fresh dialysis liquid (not shown).

20

25

A ultrafiltration pipe 8 is connected to the drain pipe 18 between the filter 4 and the pump 20 and is fitted with an ultrafiltration pump 21 supplying a flow UFR.

An infusion pipe 9 is connected to the extracorporeal blood circuit 2. It comprises a main pipe 22, which forks into

8

a pre-dilution pipe 25 connected to the arterial bubble trap 14 and a post-dilution pipe 26 connected to the venous bubble trap 16. The main pipe 9 is fitted with an infusion pump 23 supplying a flow IR. A valve set 24 is arranged directly downstream from the fork on the pre-dilution and post-dilution pipes 25, 26. In use, the upstream end of the main pipe 22 is connected to a source of sterile solution (not shown).

5

10

15

20

25

A compressed air line 10 comprises a main pipe 27 which forks into two secondary pipes 29 and 30, respectively connected to the arterial and venous bubble traps 14, 15. A valve set 28 is arranged at the connection between the main and secondary air pipes.

The control circuit 11 comprises a control unit 31, a sensor 32 positioned on the arterial pipe 12 directly upstream from the filter 4 for supplying a signal Pbi correlated to the blood pressure at the inlet of the filter 4, a sensor 33 positioned on the venous pipe 15 directly downstream from the filter 4 for supplying a signal Pbo correlated to the blood pressure at the outlet of the filter 4, a sensor 34 positioned on the supply pipe 17 for supplying a signal Pdi correlated to the pressure of the dialysis liquid at the inlet of the filter 4, and a sensor 35 positioned on the drain pipe 18 for supplying a signal Pdo correlated to the pressure of the dialysis liquid at the outlet of the filter 4. The control circuit 11 also comprises a haemoconcentration sensor 36 arranged along pipe 12 between the filter 4 and the bubble trap 14 for producing a haemoconcentration signal CE.

9

The signals Pbi, Pbo, Pdi, Pdo and CE and the set values of various parameters, such as the blood flow rate Qb, the flow rates (Qdi, Qdo) of the dialysis liquid in the supply pipe 17 and in the drain pipe 18, the ultrafiltration flow rate UFR, and the infusion flow rate IR are received by the central unit 31 for controlling the operation of the machine 1. In practice, the central unit 31 emits output signals for controlling the valve sets 24 and 28, the ultrafiltration pump 21 and the infusion pump 23, as will be made clear in the rest of the description.

5

10

15

20

25

Referring to figure 2, the valve set 24 comprises a double-pinch valve 37 and an electromagnet 38 for operating the valve 37. The valve 37 is positioned on the infusion pipes 25 and 26 in a position where the pipes 25 and 26 are substantially parallel, and comprises two fixed and opposite members 39 and 40, which are arranged in contact with the pipes 25 and 26 respectively, and a movable member 41, which is positioned between the pipes 25 and 26 and between the fixed members 39 and 40. The movable element 41 is connected to a slide 42 of the electromagnet 38 and can move between a position of rest, shown by a solid line in figure 2, and two operating positions, shown by dashed lines in figure 2.

According to the variant in figure 3, the valve set 24 comprises a pinch valve 43, which comprises a cam-type movable member 44, which can rotate about an axis 45 and is caused to rotate by an electric stepping motor 46. Cam-member 43 occupies two positions of rest about axis 45, one of which is

10

shown by a solid line in Fig. 3, and two operating positions, shown by dashed lines in Fig. 3.

In use, the infusion of liquid is regulated by adjusting the delivery, by the pump 23, of a liquid (generally a solution possessing physiological composition and concentration) upstream and downstream from the filter 4.

The machine 1 operates on the basis of studies undertaken by the applicant, which demonstrated that the occurrence of some critical conditions does not depend on the absolute value of the individual quantities being monitored, but on the amount of liquid removed by ultrafiltration with respect to the plasma flow at the filter inlet.

Since the plasma flow depends on the blood flow $Q_{\rm b}$ and on the initial concentration of the blood, according to one embodiment of the invention, the values of the blood flow $Q_{\rm b}$, the ultrafiltration flow rate UFR and the concentration of the blood $C_{\rm E}$ are acquired; the filtration factor FF, defined below, is determined on the basis of these quantities:

20 FF = UFR/Q_p = UFR/[Q_b(1-Hct)]

5

10

15

25

in which $Q_{\rm p}$ is the plasma flow and Hct is the haematocrit which is related to the concentration of the blood $C_{\rm E}$. The filtration factor is a quantity that is correlated with the concentration of the blood $C_{\rm E}$. The control unit 31 compares the filtration factor FF determined using the above equation with a series of intervals $I_{1...x}$, which are each associated with corresponding values of the respective signals S, G, H, L

11

and A at the output of control unit 31. When the filtration factor FF is within a defined interval $I_{\rm X}$, the central control unit 31 ascribes defined values to the corresponding output signals G, H, S and L for operating, respectively, the valve sets 24 and 28 and/or the ultrafiltration pump 21, and the infusion pump 23.

This control situation is shown schematically in figure 1 by the control signals G, H, S and L generated by the control unit 31 and acting respectively on the valve sets 24 and 28 and on the ultrafiltration pump 21 and the infusion pump 23, and by a signal A supplied to a display unit (not shown).

10

15

20

25

The control of the operating point of filter 4 also permits its optimization. In practice, for each interval $I_{1...x}$, there is a corresponding particular operating condition of the machine 1; specifically each particular operating condition can comprise, in combination, a particular distribution of the infusion liquid in pre-dilution and in post-dilution by acting upon valve set 24, a variation of the ultrafiltration flow rate UFR by acting on the pump 21 and a variation of the infusion flow rate IR by acting on the pump 23. By adjusting the valve set 28 it is possible to change the amount of air inside the bubble traps 14 and 16 when there is a variation of the pre-dilution and post-dilution flow rates.

The concentration of the blood CE can be measured directly, via the haematocrit Hct, or indirectly by measuring the haemoglobin (in which case the value of the haematocrit Hct is obtained by dividing the measured haemoglobin value Hgb by the cellular mean concentration of the haemoglobin (Hcmc)

12

or by measurements of the viscosity, the electrical conductivity or the density of the blood, in a known manner which will not be described in detail).

The signals S and L are for controlling the motors of the pumps 21 and 23 so as to increase or decrease the flow rates UFR and IR.

The signal H is for controlling the valve set 28 and for determining the amount of air in the bubble traps 14 and 16 in relation to the pre-dilution and post-dilution flow rates.

10

20

25

Referring to figure 2, the signal G is a control signal for exciting the electromagnet 38 according to a predetermined sequence. In other words, the distribution of the infusion flow in the two pipes 25, 26 results from the alternate opening and closing of the pre-dilution and post-dilution pipes 25 and 26 by means of the movable member 41 operated by electromagnet 38 according to a sequence defined by signal G.

The control sequences comprise, in addition to the combined operating mode between pre-dilution and post-dilution, also the exclusive pre-dilution operating mode and the exclusive post-dilution operating mode. The movable member 41 is displaced alternately against the fixed members 39 and 40 so as to pinch the infusion pipes 25 and 26 alternately and so as to interrupt the infusion flow in pipes 25 and 26 cyclically and according to a defined sequence.

The valve set 24 in figure 3 operates like the valve set in figure 2, so as to cause the alternation of the closed position of the pipes 25 and 26. In this case, the signal G defines a particular sequence of the angular position of the

13

motor 46 which determines, in turn, the position of the movable member 44.

According to one variant of the invention, the predilution and post-dilution positions together with the ultrafiltration flow rate UFR and the infusion flow rate IR are adjusted in relation to the mean transmembrane values:

 $TMP_{ave} = [TMP_i - TMP_o]/2$

25

calculated from the four pressures measured at the inlet and outlet of the blood compartment 5 and of the dialysis liquid compartment 6 of the filter 4, (in this formula, TMP; is the transmembrane pressure value, which is equal to the difference between the pressure value (Pbi) at the inlet of the blood compartment (5) and the pressure value (Pdo) at the outlet of the dialysis liquid compartment (6), and TMPo is the outlet transmembrane pressure value, which is equal to the difference between the pressure value (Pbo) at the outlet of the blood compartment (5) and the pressure value (Pdi) at the inlet of the dialysis liquid compartment (6)).

Here also, the mean transmembrane values are compared with respective intervals $IT_{1...x}$, which are each associated with corresponding respective signals G, H, S and L for operating the valve sets 24 and 28, the ultrafiltration pump 21 and the infusion pump 23.

According to another variant, pre-dilution and post-dilution positions together with the flow rates of

14

ultrafiltration UFR and infusion IR are regulated in relation to the actual permeability values of the membrane, defined as:

Kuf = UFR/TMPave

5

10

15

20

25

The values of the actual permeability $K_{\rm uf}$ are compared with respective intervals $IK_{1...x}$, which are each associated with corresponding respective signals G, H, L and S for operating the valve sets 24 and 28, the ultrafiltration pump 21 and the infusion pump 23.

The techniques for determining the operating conditions of the filter 4 and the state of the membrane 7 can be applied individually as described above or in combination as described in the applicant's patent application TO99000680 filed on 30 July 1999.

The method based on the filtration factor FF can be employed in combination either with the method based on the mean transmembrane values TMP_{ave} , or with the method based on the permeability values K_{uf} .

The advantages of the present method are clear from the above description. It is emphasized, in particular, that the present method permits accurate regulation and distribution of the infusion flow rate IR. Moreover, since the present method is based on the monitoring of quantities that are directly correlated with the operating conditions of the filter 4, it immediately supplies the magnitude of the changes required, or at any rate greatly simplifies the determination of these changes, for the purpose of improving the filtration

15

efficiency and avoiding critical situations. Furthermore, the present method does not require modification of the dialysis machine, since the control unit 31 can be implemented with the unit, already provided, for controlling the dialysis treatment, and the quantities employed are already available or can easily be obtained by mathematical methods from the measured or imposed quantities.

CLAIMS

15

- 1. Dialysis machine comprising:
- a filter (4) having a blood compartment (5) and a dialysis liquid compartment (6) separated by a semi-permeable membrane (7);
- an extracorporeal blood circuit having an arterial pipe (12) connected to an inlet of the blood compartment (5) and a venous pipe (15) connected to an outlet of the blood compartment (5);
- a dialysis liquid circuit having a supply pipe (17)

 10 connected to an inlet of the dialysis liquid compartment (6)

 and a drain pipe (18) connected to an outlet of the dialysis

 liquid compartment (6);
 - an infusion circuit having a pre-dilution pipe (25) connected to the arterial pipe (12) and a post-dilution pipe (26) connected to the venous pipe (15);

characterized in that it comprises:

- means (23, 24) for varying the flow of an infusion liquid in the pre-dilution pipe (25) and in the post-dilution pipe (26), and
- control means (31) for controlling the flow varying means (23, 24) so that the flow of the infusion liquid in the pre-dilution pipe (25) and the post-dilution (26) pipe matches a determined sequence.
- 2. Dialysis machine according to claim 1, characterized in that the control means (31) comprises means for determining the infusion sequence from at least one characteristic value

17

(FF, TMP_{ave}, K_{uf}) correlated with the concentration of the blood (C_E) and/or the filtration efficiency of the filter (4).

3. Dialysis machine according to claim 2, characterized in that the control means (31) comprises means for comparing the characteristic value (FF, TMPave, Kuf) with a series of intervals (I1...x, IT1...x, IK1...x), each interval (I1...x, IT1...x, IK1...x) being associated with at least a predetermined control signal (S, G, H, L).

10

15

20

- 4. Dialysis machine according to claim 3, characterized in that the infusion varying means comprises a valve means (24) for alternately occluding the pre-dilution pipe (25) and the post-dilution pipe (26), and in that the predetermined control signal (G) defines a sequence for opening and closing the valve means (24).
- 5. Dialysis machine according to one of the claims 3 and 4, characterized in that the infusion varying means comprises an infusion pump (23) for circulating the infusion liquid, and in that the predetermined control signal (L) is for regulating the flow rate (IR) of liquid generated by the infusion pump (23).
- 6. Dialysis machine according to one of the claims 3 to 5, characterized in that it comprises a ultrafiltration pump (21) for causing ultrafiltration of plasma water through the membrane (7) of the filter (4), and in that the predetermined

18

control signal (S) is for regulating the flow rate (UFR) of liquid generated by the ultrafiltration pump (21).

- 7. Dialysis machine according to one of the claims 3 to 6, characterized in that it comprises a bubble trap (14) connected to the arterial pipe (12) and a bubble trap (16) connected to the venous pipe (15) and means (27, 28) for injecting or withdrawing air into/from the bubble traps (14, 16) so as to adjust the level of liquid therein, and in that the predetermined control signal (S) is for controlling the means (27, 28) for injecting or withdrawing air into/from the bubble traps (14, 16).
- 8. Dialysis machine according to one of the claims 2 to 7, characterized in that it comprises:
 - means for determining a ultrafiltration flow rate (UFR) of plasma water through the membrane (7) of the filter (4);
 - means (11) for determining the haematocrit (Hct) at the inlet of the filter (4), and
- means (31) for calculating the characteristic value as a filtration factor (FF) equal to UFR/[Qb(1-Hct)].
- 9. Dialysis machine according to claim 8, characterized in that the means for determining the haematocrit (Hct) comprises means for determining the haemoglobin concentration (11) at the inlet of the filter (4) and means (31) for dividing the haemoglobin concentration by a constant coefficient.

- 10. Dialysis machine according to one of the claims 2 to 7, characterized in that it comprises:
- means (32, 33) for measuring the blood pressure values (P_{bo}, P_{bi}) at the inlet and at the outlet of the blood compartment (5) of the filter (4);
- means (34, 35) for measuring the dialysis liquid pressure values (Pdi, Pdo) at the inlet and at the outlet of the dialysis liquid compartment (6) of the filter (4);
- means (31) for calculating an inlet transmembrane pressure value (TMPi) as the difference between the pressure value (Pbi) at the inlet of the blood compartment (5) and the pressure value (Pdo) at the outlet of the dialysis liquid compartment (6) and an outlet transmembrane pressure value (TMPo) as the difference between the pressure value (Pbo) at the outlet of the blood compartment (5) and the pressure value (Pdi) at the inlet of the dialysis liquid compartment (6);
 - means (31) for calculating the characteristic value as a mean transmembrane pressure value (TMPave) equal to [TMPi-TMPo]/2.

20

25

- 11. Dialysis machine according to claim 10, characterized in that it comprises:
- means for determining a ultrafiltration flow rate (UFR)
 of plasma water through the membrane of the filter (4);
- means (31) for calculating the characteristic value as an actual permeability ($K_{\rm uf}$) equal to the ratio between the ultrafiltration flow rate (UFR) and the mean transmembrane pressure value (TMPave).

PCT/IB01/00544

5

10

12. Method for infusing an infusion liquid in an extracorporeal blood circuit of a dialysis liquid machine, the extracorporeal blood circuit having an arterial pipe (12) connected to an inlet of a blood compartment (5) of a filter (4), and a venous pipe (15) connected to an outlet of the blood compartment (5), the filter (4) having a blood compartment (5) and a dialysis liquid compartment (6) separated by a semi-permeable membrane (7),

characterized in that it comprises the steps of;

- determining an infusion sequence from at least one characteristic value (FF, TMP_{aVe} , K_{uf}) correlated with the concentration of the blood (CE) and/or a filtration efficiency of the filter (4), and
- infusing the infusion solution in either one or both of the arterial pipe (12) and the venous pipe (15) in accordance with the determined infusion sequence.
- it comprises the step of comparing the characteristic value (FF, TMPave, Kuf) with a series of intervals (I1...x, IT1...x, IK1...x), each interval (I1...x, IT1...x, IT1...x, IK1...x) being associated with at least a predetermined control signal (S, G, H, L).

25

14. Method according to claim 13, characterized in that the predetermined control signal (G) defines a sequence for opening and closing a valve means (24) arranged for

alternately occluding a pre-dilution infusion pipe (25) connected to the arterial line (12) and a post-dilution infusion pipe (26) connected to the venous line (15).

21

- 15. Method according to one of the claims 13 and 14, characterized in that the predetermined control signal (L) is for regulating the flow rate (IR) of liquid generated by an infusion pump (23) for circulating the infusion liquid
- 16. Method according to one of the claims 13 to 15, characterized in that predetermined control signal (S) is for regulating the flow rate (UFR) of liquid generated by a ultrafiltration pump (21) for causing ultrafiltration of plasma water through the membrane of the filter (4).

15

20

- 17. Method according to one of the claims 13 to 16, characterized in that the predetermined control signal (S) is for controlling means (27, 28) for injecting or withdrawing air into/from bubble traps (14, 16) respectively connected to the arterial pipe (12) and to the venous pipe (15).
- 18. Method according to one of the claims 12 to 17, characterized in that it comprises the steps of:
- determining a ultrafiltration flow rate (UFR) of plasma
 water through the membrane (7) of the filter (4);
 - determining the haematocrit (Hct) at the inlet of the filter (4), and
 - calculating the characteristic value as a filtration factor (FF) equal to UFR/[Qb(1-Hct)].

PCT/IB01/00544

WO 01/76661

15

20


22


- 19. Method according to claim 18, characterized in that the step of determining the haematocrit (Hct) comprises the step of determining the haemoglobin concentration at the inlet of the filter (4) and the step of dividing the haemoglobin concentration by a constant coefficient.
- 20. Method according to one of the claims 12 to 17, characterized in that it comprises the steps of:
- measuring the blood pressure values (Pbo, Pbi) at the inlet and at the outlet of the blood compartment (5) of the filter (4);
 - measuring the dialysis liquid pressure values (P_{di} , P_{do}) at the inlet and at the outlet of the dialysis liquid compartment (6) of the filter (4);
 - calculating an inlet transmembrane pressure value (TMP_i) as the difference between the pressure value (P_{bi}) at the inlet of the blood compartment (5) and the pressure value (P_{do}) at the outlet of the dialysis liquid compartment (6) and an outlet transmembrane pressure value (TMP_o) as the difference between the pressure value (P_{bo}) at the outlet of the blood compartment (5) and the pressure value (P_{di}) at the inlet of the dialysis liquid compartment (6);
- calculating the characteristic value as a mean 25 transmembrane pressure value (TMPave) equal to [TMPi-TMPo]/2.
 - 21. Method according to claim 20, characterized in that it comprises the steps of:


determining a ultrafiltration flow rate (UFR) of plasma
 water (7) through the membrane of the filter (4);

23

• calculating the characteristic value as an actual permeability ($K_{\rm uf}$) equal to the ratio between the ultrafiltration flow rate (UFR) and the mean transmembrane pressure value ($TMP_{\rm ave}$).







A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61M1/34 A61M1/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7-A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

(CH)) 12 November 1998 (1998–11–12) page 10, line 22 –page 12, line 31 figure 1 Z-4 DE 196 54 746 A (SODEMANN KLAUS DR MED) 2 July 1998 (1998–07–02) column 3, line 35 – line 60 column 5, line 15 – line 25 figure 1 WO 00 09182 A (KAHN JEAN MAURICE; ALPAMED S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 Ye page 6, line 25 – line 26 The start defining the general state of the art which is not considered to be of particular relevance: The start document but published on or after the international filing date on which is cited to establish the publication date of another citation or other special reason (as specified) To document referring to an oral disclosure, use, exhibition or other means The document published prior to the international filing date but the combined with one or more other such documents such combined with one or more other such documents. The start referring to an oral disclosure, use, exhibition or other means The document published prior to the international filing date but the combination being obvious to a person skilled in the art which is not considered to more other such documents is combined with one or more other such documents. The start reduction of the international filing date but the combination being obvious to a person skilled in the art which is not considered to not one of the combination being obvious to a person skilled in the art which is not considered to not one of the combination being obvious to a person skilled in the art which is not considered to not one of the art which is not considered to not in conflict with the application but skilled after the international filing date the international filing date and not in conflict with the application but skilled after the international filing date and not in conflict with the application but skilled after the international filing date and not in conflict with the application but skilled after the international filing date and not in conflict wi	(CH)) 12 November 1998 (1998–11–12) page 10, line 22 –page 12, line 31 figure 1 Z-4 X DE 196 54 746 A (SODEMANN KLAUS DR MED) 2 July 1998 (1998–07–02) column 3, line 35 – line 60 column 5, line 15 – line 25 figure 1 X WO 00 09182 A (KAHN JEAN MAURICE; ALPAMED X A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 X Patent family members are listed in annex. Y a document defining the general state of the art which is not considered to be of particular relevance E earlier document but published on or after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention cannot be considered to love or cannot be considered to involve an inventive step when the document its taken alone of the repeated irreason (as specified) C document referring to an oral disclosure, use, exhibition or other means	Category °	Citation of document, with indication, where appropriate, of	Relevant to claim No.	
A DE 196 54 746 A (SODEMANN KLAUS DR MED) 2 July 1998 (1998–07–02) column 3, line 35 – line 60 column 5, line 15 – line 25 figure 1 X WO 00 09182 A (KAHN JEAN MAURICE ; ALPAMED S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 X Further documents are listed in the continuation of box C. Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'C' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but The tater document published after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention cannot be considered to be considered to be considered to involve an inventive step when the document is taken alone of document referring to an oral disclosure, use, exhibition or other means P' document published prior to the international filing date but	A DE 196 54 746 A (SODEMANN KLAUS DR MED) 2 July 1998 (1998–07–02) column 3, line 35 – line 60 column 5, line 15 – line 25 figure 1 X WO 00 09182 A (KAHN JEAN MAURICE; ALPAMED S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 X Further documents are listed in the continuation of box C. Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance 'A' document defining the general state of the art which is not considered to be of particular relevance 'A' document defining the general state of the art which is not considered to be of particular relevance 'A' document defining the general state of the art which is not considered to be of particular relevance 'A' document defining the general state of the art which is not considered to be of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered invention or one of particular relevance; the claimed invention cannot be considered invention cannot be considered invention or one of the such documents; such combinated with one or more other such document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the document is taken alone voice and inventive step when the docu	Х	(CH)) 12 November 1998 (1998- page 10, line 22 -page 12, li	1	
2 July 1998 (1998–07–02) column 3, line 35 – line 60 column 5, line 15 – line 25 figure 1 X WO 00 09182 A (KAHN JEAN MAURICE; ALPAMED S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 X Patent family members are listed in annex. *Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published or or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other special reason (as specified) 'O' document published prior to the international filing date but 'P' document published prior to the international filing date but	Z July 1998 (1998–07–02) column 3, line 35 – line 60 column 5, line 15 – line 25 figure 1 WO 00 09182 A (KAHN JEAN MAURICE; ALPAMED S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 "Y Patent family members are listed in annex. "Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance; "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another clation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "P" document published prior to the international filing date but later than the priority date claimed "P" document published prior to the international filing date but later than the priority date claimed	Α			2–4
S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 – line 15 page 6, line 25 – line 26 X Further documents are listed in the continuation of box C. X Patent family members are listed in annex. *Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is combined with one or more other such document is	S A (CH); JUNOD MICHEL (CH); LEVEQUE ER) 24 February 2000 (2000–02–24) page 5, line 9 - line 15 page 6, line 25 - line 26 X Further documents are listed in the continuation of box C. Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'P' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'P' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published prior to the international filing date but later than the priority date claimed 'P' document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the	X	2 July 1998 (1998-07-02) column 3, line 35 - line 60 column 5, line 15 - line 25	US DR MED)	
Further documents are listed in the continuation of box C. Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published after the international filing date "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combined with one or more other such documents, such combination being obvious to a person skilled in the art.	Further documents are listed in the continuation of box C. Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "A" tater document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone to comment of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family	X	S A (CH); JUNOD MICHEL (CH); 24 February 2000 (2000-02-24) page 5, line 9 - line 15	LEVEQUE ER)	1
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but "I tater document published and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	*A' document defining the general state of the art which is not considered to be of particular relevance *E' earlier document but published on or after the international filing date *L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O' document referring to an oral disclosure, use, exhibition or other means *P' document published prior to the international filing date but later than the priority date claimed *I' after document published and not in conflict with the application but cited to understand the principle or theory underlying the invention or particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *A' document member of the same patent family	X Fur	ther documents are listed in the continuation of box C.		d in annex.
later than the phorny date claimed a document member of the same patent manage	Date of the actual completion of the international search Date of mailing of the international search report	"A" docum consi "E" earlier filing "L" docum which citatic "O" docum other	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or means sent published prior to the international filing date but	or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the description of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious in the art.	h the application but neory underlying the claimed invention of the considered to cournent is taken alone claimed invention nventive step when the lore other such docupous to a person skilled

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Authorized officer

Lakkis, A

		PC1/1B 01/00544				
C.(Continu	(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
A	DE 42 40 681 A (FRESENIUS AG) 9 June 1994 (1994-06-09) column 6, line 20 -column 8, line 39 figure 2	.1				
E	EP 1 095 666 A (INFOMED S A) 2 May 2001 (2001-05-02) the whole document	1,2				
E	EP 1 097 724 A (HOSPAL IND) 9 May 2001 (2001-05-09) the whole document	1				

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter nal Application No PCT/IB 01/00544

	Publication date		atent family nember(s)	Publication date
Α	12-11-1998	AU EP	6849998 A 0980275 A	27-11-1998 23-02-2000
A	02-07-1998	WO EP	9829151 A 1011748 A	09-07-1998 28-06-2000
Α	24-02-2000	NONE		
Α	09-06-1994	NONE		
Α	02-05-2001	WO	0132238 A	10-05-2001
Α	09-05-2001	FR AU	2800618 A 6956200 A	11-05-2001 10-05-2001
	A A A	A 02-07-1998 A 24-02-2000 A 09-06-1994 A 02-05-2001	EP A 02-07-1998 WO EP A 24-02-2000 NONE A 09-06-1994 NONE A 02-05-2001 WO A 09-05-2001 FR	EP 0980275 A A 02-07-1998 WO 9829151 A EP 1011748 A A 24-02-2000 NONE A 09-06-1994 NONE A 02-05-2001 WO 0132238 A A 09-05-2001 FR 2800618 A